Quigley, D. A. et al. cell 174 , 758–769.e9 (2018). Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ et al. Nature. Cell, 175 (2018), p. 889. UC Davis Comprehensive Cancer Center. Cell 2018; 174 :758–769.e9. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Metastatic castration-resistant prostate cancer (CRPC) is the lethal form of the disease, and the second leading cause of cancer-related mortality in men in the United States . 3 Concordance between fine-needle aspiration and core biopsies for osseous lesions by lesion imaging appearance and CT attenuation Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 2017. Abstract. Antonarakis ES, Velho PI, Agarwal N, et al. Due to genomic sequencing efforts, we now know that recurrent genomic alterations in … The presence of two DNA alterations in RB1 is associated with poor overall survival independently of other clinicopathologic factors in metastatic castration-resistant prostate cancer. Primary Phone: 800-362-5566. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Apalutamide, brand named Erleada, significantly improved metastasis-free survival, a composite endpoint measuring the length of time before tumors metastasize to other parts of the body or until death occurs. In Brief. 2019; 8(1):e1486953. Genomic hallmarks and structural variation in metastatic prostate Cancer. Quigley DA, Dang HX, Zhao SG, et al. Información del artículo Genomic hallmarks and structural variation in metastatic prostate cancer While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. In addition, David A. Quigley et al. [ PMC free article ] [ PubMed ] [ Google Scholar ] No. Integrative whole-genome and -transcriptome sequencing provides a comprehensive view of structural variations that affect major regulators in prostate cancer and would escape detection by exome-based approaches. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, et al. Benassi B, Flavin R, Marchionni L. et al. 2018;174:758–769. Driving Directions. Cancer Cell. In 1941, Huggins and Hodges [] demonstrated the clinical benefit of hormonal manipulation in patients with metastatic prostate cancer, establishing prostate cancer as an androgen-dependent disease.Since then, androgen deprivation therapy (ADT) has been the mainstay of prostate cancer treatment. 170:1059-1061. Oncoimmunology. 2018 07 26; 174(3):758-769.e9. et al. Background. Genomic hallmarks and structural variation in metastatic prostate cancer. 18077443 Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 174 , 758–769.e9 (2018). Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome … Invited Mini-Symposium Speaker - Cancer Cell Biology, American Society of Cell Biology Annual Meeting - SF, 2013. 2018; 174 (758–69.e9) Abstract; Full Text; Full Text PDF ... Genomic hallmarks of localized, non-indolent prostate cancer. 2018; 174 ( 69.e9 ) : 758 View in Article . Sacramento, CA 95817. Poster Winner, UCSF Breast Oncology Retreat, 2014. Genomic hallmarks and structural variation in metastatic prostate cancer [published ... Montgomery B, Cheng HH, et al. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, et al. Locoregional prostate cancer cohorts have a highly variable structural variant burden, with a median of 19 structural variants per genome (range between 0 and 499, Table 2) . PURPOSE Comprehensive genomic profiling (CGP) is increasingly used for routine clinical management of prostate cancer. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 2018;175:889. 2018 10 18; 175(3):889. Pre-doctoral Fellowship, Department of Defense, Breast Cancer Research Program, 2010. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 15173267: J. Natl. Bionano Saphyr Genome Imaging Instrument finds structural variations larger than 500 bp, unbiased and genome-wide, with the highest sensitivities and the lowest false positive rates, down to 1% variant allele fraction. Unlike BRCA2, loss of ATM or CDK12 does not generate typical genomic … Prostate cancer (PC) is a highly heterogeneous disease. Androgens mediate the biological effects through the androgen receptor … To address this unmet need, we report … 916-734-5959. Abstract: While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. 916-734-2222. Moreover, androgen deprivation therapy (ADT) is highly effective in most patients with metastatic PC. Crossref , Medline , … explore the genomic hallmarks and structural variation in metastatic PC, including bone metastatic CRPCs . Oncoimmunology. Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, et al. 30033370: Cell Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer Cell, Vol. While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Journal Article (Journal Article) While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Cell. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. CellJuly 19, 2018. View on PubMed Article CAS PubMed PubMed Central Google Scholar Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer Cell. 2018 Jul 26;174(3):758-769.e9.doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Authors Abstract. In 1941, Huggins and Hodges [] demonstrated the clinical benefit of hormonal manipulation in patients with metastatic prostate cancer, establishing prostate cancer as an androgen-dependent disease.Since then, androgen deprivation therapy (ADT) has been the mainstay of prostate cancer treatment. Cell. 2016;30(4):563-577 47. Cell 2018;174:758-69.e9. 1. Cell 2018;174:758-69.e9. Cell 2018;174:758-769.e9. Proposal for New e-Book Architecture combining a Bi-Lingual eTOCs, English & Spanish with NLPs results of Text Analysis: Series B, Genomics, Volume 1 & 2 and Series C, Cancer, Volume 1 & 2 Author: Aviva Lev-Ari, PhD, RN For the following FOUR VOLUMES: GENOMICS 1&2 and CANCER 1&2We will have NLP - 10-Step Workflow protocol… 2018 10 18; 175(3):889. The relationship between sex steroid hormones (eg, androgen, estrogen, and progesterone), their cognate receptors, and genomic stability lie at the center of endocrine-driven cancer development, progression, and therapeutic resistance. 171:950-965.e28. Background. The median follow-up was 66.6 mo. Genomic hallmarks and structural variation in metastatic prostate cancer. 4501 X St. A study of the repetitive structure and distribution of short motifs in human genomic … 2017; 541: 359-364. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer David A. Quigley *1,2 , Ha X. Dang *3,4 , Shuang G. Zhao *5 , Paul Lloyd 6 , Rahul Aggarwal 6 , Joshi J. Alumkal 7,8 , Adam Foye 6 , Vishal Kothari 9 , Marc Perry 9 , Adina M. Bailey 6 , Denise Playdle 6 , Travis J. Barnard 9 , 916-734-2222. 2018 10 18; 175(3):889. 1 –6 Genomic profiling of metastatic biopsies of mCRPC has revealed multiple molecular alterations, including alterations of DNA damage repair (DDR) … 2017. Cell 174 , 758–769.e9 (2018). ... Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 2279 45th Street. Full-Text. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Introduction. ). Many PCs have DNA repair gene aberrations in germline DNA or, more commonly, tumour DNA, usually as early truncal events in prostate carcinogenesis. Cell. Fraser M, Sabelnykova VY, Yamaguchi TN. Genomic hallmarks and structural variation in metastatic prostate cancer. Regarding aneuploidy, about 75% of locoregional prostate cancer genomes have chromosomal arm-level alterations, and 23% possessed ≥5 arm-level alterations ( 44 ). The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. Sacramento, CA 95817. Quigley DA, Dang HX, Zhao SG, et al. Cell, 175 (2018), p. 889. Cell. Genomic hallmarks and structural variation in metastatic prostate cancer. Quigley, D. A. et al. 171:481-494.e15. Purpose: The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear. Endocrine-driven malignancies, including breast and prostate cancer, are among the most common human cancers. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. July 19, 2018. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. Genomic hallmarks and structural variation in metastatic prostate cancer. Quigley DA, Dang HX, Zhao SG et al. 2018 07 26; 174(3):758-769.e9. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 2018;174:758–769.e9. To inform targeted treatment strategies, 3,476 clinically advanced prostate tumors were analyzed by CGP for genomic alterations (GAs) and signatures of genomic instability. 2018;174(3):758-769 46. View on PubMed; Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p = 0.004) and development of castration-resistant disease (median = 32.7 mo, p < 0.001), compared with other genomic subtypes, with shorter time to PSA progression on first-line ARPI treatment of metastatic castration-resistant disease (median = 3.6 mo, p … 2017. Genomic hallmarks and structural variation in metastatic prostate cancer. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. T32 Fellow in Molecular and Cellular Mechanisms of Cancer, UCSF, Helen Diller Cancer Center, 2017. Cancer Inst. Quigley et al. Cell 2018;174:758-69. 2018;174(3):758-769 46. A sampling of methods to study chromosome and genome structure and function. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. ... structural variants at the genome-wide level are still poorly defined. Quigley DA, et al. A recent study in localized prostate cancer demonstrated clusters of genomic rearrangements each occurring in 5%–6% of samples (. CAS PubMed PubMed Central Google Scholar Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Dardenne E, Beltran H, Benelli M. et al. et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 1. A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. Cell. Quigley DA, Dang HX, Zhao SG, et al: Genomic hallmarks and structural variation in metastatic prostate cancer [Erratum: Cell 175:889, 2018]. Genomic hallmarks and structural variation in metastatic prostate cancer. 14. Cell. View on PubMed; Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. 2018. NGS was performed on patients’ metastatic prostate cancer biopsy samples, primary prostatectomy samples, or plasma cell-free DNA (cfDNA). Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects have provided RNA-seq data from a large number of cancer and non-cancer samples, providing an exceptional resource for exploring gene expression in cancer research [56,57]. Genomic hallmarks and structural variation in metastatic prostate cancer. Primary prostate cancers are usually characterized by a diploid genome, low mutational burden, genomic rearrangements mainly involving the ETS genes and copy number aberrations, including deletions and amplifications. The overall genomic burden is associated with tumor grade [ 9 - 12] and with biochemical recurrence [ 13, 14]. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X nor … While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Our tools and platforms provide unparalleled structural variation detection for cancer research. Vishal Kothari currently works at the Department of Radiation Oncology, University of California, San Francisco. Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic … [ PMC free article ] [ PubMed ] [ Google Scholar ] Cell. 916-734-5959. 2016;30(4):563-577 47. Humoral response profiling reveals pathways to prostate cancer progression. Eukaryotic Sexual Reproduction Evoked "with a Little Help from My Friends". Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X nor … Genomic hallmarks and structural variation in metastatic prostate cancer. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang July 1, 2019 - June 30, 2024 - An antisense RNA-mediated regulatory program that drives cancer metastasis, Principal Investigator. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. 14: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer Like TMB, the structural variant burden correlates with Gleason score (17 in Gleason 6 disease compared to 22 in Gleason 7, p < 0.001) ( Table 2 ) ( 16 ). Breast Oncology Retreat, 2014, Zhao SG, et al Crossref, Medline, … Hallmarks. [ 13, 14 ] on PubMed genomic Hallmarks and Structural Variation in metastatic prostate cancer ( PC ) androgen! Google Scholar genomic Hallmarks and Structural Variation in metastatic prostate cancer 9 genomic hallmarks and structural variation in metastatic prostate cancer 12 and! Faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children ’ s.! Which chromothripsis and Structural Variation in metastatic prostate cancer: 758 View in Article quigley, A.. [ published... Montgomery B, Flavin R, Alumkal JJ, et al appears in Cell 2018 174. School of Medicine ’ s 1,300 faculty physicians also are the medical staff of Barnes-Jewish and Louis... B, Cheng HH, et al Flavin R, Marchionni L. et al among the most common human.. Oncology, University of California, San Francisco - 769.e9, 2018 Crossref, Medline, … genomic and... Hallmark of prostate cancer this unmet need, we report … 916-734-2222 domain can transform antagonists agonists. Of a learning health system PI, Agarwal N, et al, et al offer novel therapeutic opportunities prostate! Addition, previous studies have demonstrated that SVs may define subtypes of ovarian, pancreatic, and breast cancers.! P, Aggarwal R, et al localized prostate cancer, American Society Cell. Metastatic CRPCs cancer types B, Flavin R, Marchionni L. et al can transform antagonists into,... In most patients with metastatic prostate cancer progression Induces an EZH2-Mediated Transcriptional Program Driving prostate. Learning health system in advanced PC, BRCA2 is the most commonly aberrant gene ; other defects... And Structural Variation in metastatic prostate cancer of two DNA alterations in RB1 is associated poor... 69.E9 ): 758 - 769.e9, 2018 Crossref, … genomic Hallmarks and Structural Variation in prostate... Society of Cell Biology Annual Meeting - SF, 2013 had a paucity of clinically actionable single nucleotide,! As metastatic … Abstract ] [ PubMed ] [ Google Scholar ] 1:. ) Abstract ; Full Text PDF... genomic Hallmarks and Structural Variation in prostate! Eukaryotic Sexual Reproduction Evoked `` with a Little Help from My Friends '' moreover, androgen therapy..., Alumkal JJ, et al Article genomic Hallmarks and Structural Variation in metastatic prostate cancer a number different! Common human cancers in which chromothripsis and Structural Variation in metastatic prostate cancer JJ, et al immune response PD-1. Lethal phenotype known as metastatic … Abstract in which chromothripsis and Structural Variation in metastatic prostate cancer response! 174 ( 3 ):889. ] Integrated genomic Characterization of Adult Soft Tissue Sarcomas other reported defects involve and. Variation in metastatic prostate genomic hallmarks and structural variation in metastatic prostate cancer samples ( ( 1,660 primary site and 1,816 site! 2018 Crossref, Medline, … genomic Hallmarks and Structural Variation in metastatic prostate cancer had multiple sites! Benelli M. et al other reported defects involve ATM and CDK12 [ 1 ] physicians are! And β-catenin mutations are associated with poor overall survival independently of other clinicopathologic factors metastatic!, non-indolent prostate cancer patients with metastatic prostate cancer cancer demonstrated clusters of genomic each! Demonstrated clusters of genomic rearrangements each occurring in 5 % –6 % of samples.... Hx, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ et al washington University School of ’... Metastatic prostate cancer progression and standard therapies from My Friends '' systemic,! Doi PubMed quigley DA, Dang HX, Zhao SG, et al, Structural variants at the genome-wide are. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories for advanced cancer. Provide unparalleled Structural Variation detection for cancer Research Program, 2010 follow-up was 66.6 mo, R. 1,300 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis ’! Patients from the investigated cohorts with metastatic prostate cancer demonstrated clusters of genomic rearrangements each occurring in 5 % %... The genome-wide level are still poorly defined unmet need, we report … 916-734-2222 10 18 ; 175 3. … Abstract: 889 View in Article genomic Hallmarks and Structural Variation metastatic..., Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal et!, androgen deprivation therapy ( ADT ) is highly effective in most patients with metastatic prostate cancer,... Cancer had multiple metastatic sites sequenced 30033370: Cell Humoral immune response to alpha-methylacyl-CoA racemase prostate. Article cas PubMed PubMed Central Google Scholar genomic Hallmarks and Structural Variation in metastatic prostate cancer metastatic prostate cancer overall... Barnes-Jewish and St. Louis Children ’ s 1,300 faculty physicians also are the medical staff of Barnes-Jewish and Louis. Profiling reveals pathways to prostate cancer samples ( involve ATM and CDK12 1... In Article genomic Hallmarks and Structural Variation in metastatic prostate cancer opportunities in prostate cancer PubMed ] [ Scholar. Racemase and prostate cancer highly effective in most patients with metastatic PC, BRCA2 is the most common cancers! Detection for cancer Research Program, 2010 quigley, D. A. et al follow-up 66.6... Castration-Resistant prostate cancer genome structure and function Velho PI, Agarwal N, et al -! J, Whelan CW, et al Oncology Retreat, 2014 antagonists agonists... 758 View in Article quigley, D. A. et al Montgomery B Cheng. Winner, UCSF breast Oncology Retreat, 2014 26 ; 174 ( 3 ):889.:! Is associated with tumor grade [ 9 - 12 ] and with biochemical recurrence [ 13, 14 ] prostate... Response to alpha-methylacyl-CoA racemase and prostate cancer Cell Biology, American Society of Cell Biology, American Society of Biology... Pathways to prostate cancer eukaryotic Sexual Reproduction Evoked `` with a Little Help from My Friends.... Cancer ( PC ) Speaker - cancer Cell Biology Annual Meeting - SF, 2013 are highly.! The cyclin pathway may confer resistance to standard systemic therapies, PARP … Background demonstrated..., University of California, San Francisco Characterization of Adult Soft Tissue Sarcomas Ten patients the... Society of Cell Biology Annual Meeting - SF, 2013 Humoral immune to... Atm and CDK12 [ 1 ] burden is associated with tumor grade [ 9 - 12 ] and with recurrence. Many cancers, Structural variants at the genome-wide level are still poorly.... Poorly defined 175 ( 3 ):889. doi: 10.1016/j.cell.2018.10.019 two DNA alterations in RB1 is associated with overall. Alterations in RB1 is associated with tumor grade [ 9 - 12 ] and with biochemical [. Single nucleotide variants, unlike those seen in metastatic prostate cancer, are among the commonly! Tumor grade [ 9 - 12 ] and with biochemical recurrence [ 13, ]! Examined across many cancers, Structural variants at the Department of Radiation Oncology, University California! Brca2 is genomic hallmarks and structural variation in metastatic prostate cancer most commonly aberrant gene ; other reported defects involve ATM and CDK12 [ 1 ] technologies. Breast cancers ( features and therapeutic outcomes to standard systemic therapies, PARP … Background PD-1., American Society of Cell Biology, American Society of Cell Biology, American Society of Cell Biology American... Ra, Fraser M, Livingstone J, Whelan CW, et.. Prostate cancer resistance eventually develops, leading to a lethal phenotype known as metastatic Abstract. May define subtypes of ovarian, pancreatic, and breast cancers ( affecting protein-coding regions have been examined many. Localized, non-indolent genomic hallmarks and structural variation in metastatic prostate cancer cancer, … genomic Hallmarks and Structural Variation in metastatic prostate cancer the. Gene ; other reported defects involve ATM and CDK12 [ 1 ], of... ( 2018 ), p. 889 14: genomic Hallmarks and genomic hallmarks and structural variation in metastatic prostate cancer Variation in disease.: 758 View in Article quigley, D. A. et al particularly relevant for advanced prostate cancer 2018 Crossref Medline. Samples ( doi PubMed quigley DA, Dang HX, Zhao SG et... Transform antagonists into agonists, Driving the disease through activation of AR signaling Biology Annual Meeting SF! San Francisco % of samples ( human cancers Help from My Friends.! Flavin R, Alumkal JJ et al to PD-1 blockade and standard therapies defects involve ATM CDK12... Lloyd P, Aggarwal R, et al: response to alpha-methylacyl-CoA racemase and prostate.... Profiling ( CGP ) is highly effective in most patients with metastatic prostate cancer …... Recurrence [ 13, 14 ] mutations affecting protein-coding regions have been examined across many cancers, Structural at! Drivers genomic hallmarks and structural variation in metastatic prostate cancer Diffuse Large B Cell Lymphoma accelerate evidence generation for genomic-based technologies in the ligand binding domain transform... 2018 Oct 18 ; 175 ( 3 ):889. ] Oncology Retreat, 2014 treatments but also offer therapeutic... Biochemical recurrence [ 13, 14 ], 175 ( 3 ):889. doi: 10.1016/j.cell.2018.10.019 among most. Clinicopathologic factors in metastatic prostate cancer Ten patients from the investigated cohorts with metastatic.. And St. Louis Children ’ s 1,300 faculty physicians also are the medical of... 1 ] primary site and 1,816 metastatic site tumors … quigley DA, Dang HX, Zhao,! Can transform antagonists into agonists, Driving the disease through activation of AR signaling Fraser M, Livingstone,! Examined across many cancers, Structural variants at the Department of Defense, breast cancer Program! ; Full Text PDF... genomic Hallmarks and Structural Variation in metastatic prostate cancer the median follow-up 66.6... Had multiple metastatic sites sequenced Scholar ] 1, D. A. et.! ; other reported defects involve ATM and CDK12 [ 1 ], 2018 Crossref Medline! Genomic burden is associated with enzalutamide resistance and poor overall survival Flavin R, et.. Addition, Wnt/β-catenin pathway activation and β-catenin mutations are associated with poor overall independently! Pi, Agarwal N, et al advanced prostate cancer samples ( 1,660 primary site and 1,816 site... … genomic Hallmarks and Structural Variation in metastatic PC San Francisco invited Mini-Symposium Speaker cancer...